I. Katayama, M. Ashida, A. Maeda, K. Eishi, H. Murota and S. J. Bae, “Open Trial of Topical Tacalcitol [1α24(OH)2D3] and Solar Irradiation for Vitiligo Vulgaris: Upregulation of c-Kit mRNA by Cultured Melanocytes,” European Journal of Dermatology, Vol. 13, No. 4, 2003, pp. 372-376.

has been cited by the following article:

• TITLE: Therapeutic Comparison between Sun Irradiation vs. Narrowband UVB Phototherapy along with Concomitant Topical Tacalcitol for Vitiligo Vulgaris

  AUTHORS: Atsushi Tanemura, Aya Takahashi, Yuriko Ueki, Hiroyuki Murota, Yuji Yamaguchi, Ichiro Katayama

  KEYWORDS: Vitiligo; Tacalcitol; [1α24(OH)2D3]; Sun Irradiation; Narrowband UVB

  JOURNAL NAME: Journal of Cosmetics, Dermatological Sciences and Applications, Vol.2 No.2, June 22, 2012

  ABSTRACT: In addition to therapeutic options such as steroid ointment, immunosuppressive drug and ultraviolet phototherapy, recent reports have demonstrated the clinical efficacy of topical vitamin D3 for vitiligo vulgaris. However, there seems to be little clinical effect of vitamin D3 without UV exposure. In the present study, we evaluated the clinical difference of sun irradiation vs. narrowband UVB in combination with tacalcitol assessing the change of lesion size and color tone by a spectrophotometer. Thirty-three vitiligo patients were composed of 19 treated with sun illumination and 14 treated with narrowband UVB in combination with topical use of tacalcitol. The mean % size reduction was higher in the group of sunbathing than narrowband UVB (29% vs. 23%). Delta L score, which represented the difference of whiteness between lesional and perilesional skin, was significantly improved after treatment in the group of sun irradiation instead of narrowband UVB (p = 0.0023). Therefore, we consider that sun illumination along with tacalcitol may be able to induce natural repigmentation and be an alternative therapeutic option for vitiligo vulgaris.